IntelliCyt manufactures and sells integrated instrumentation, software and reagent solutions that facilitate the study of cells and their components to gain a better understanding of normal and disease processes. This information speeds the discovery and development of new drugs and provides new insight for the diagnosis of diseases. IntelliCyt's products are used worldwide throughout the pharmaceutical and biotechnology industries and in academic research labs.
Missing: IntelliCyt's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: IntelliCyt's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing IntelliCyt
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
IntelliCyt is included in 1 Expert Collection, including Biopharma Tech.
IntelliCyt has filed 32 patents.
Molecular biology, Biotechnology, Virology, Immunology, Flow cytometry
Molecular biology, Biotechnology, Virology, Immunology, Flow cytometry
Latest IntelliCyt News
Nov 9, 2022
How cell analysis is becoming big business: A look at the Flow Cytometry market Pune, Maharashtra, India, November 9 2022 (Wiredrelease) Prudour Pvt. Ltd –:Flow Cytometry Market to Grow at a CAGR of 8.3% From 2022-2031 The flow cytometry market is expected to grow at a compound annual growth rate of 8.3% from 2019 to 2031, according to a new report by Market.us. The growth of the flow cytometry market is driven by the increasing incidence of cancer, increasing demand for early diagnosis of disease, and the growing popularity of personalized medicine. The report says the main drivers for this growth are the increasing incidence of cancer and blood disorders, the rapidly aging population, and the increasing demand for early diagnosis. According to the report, the global flow cytometry market was valued at USD 4.8 billion in 2018 and is expected to reach USD 8.0 billion by 2031. Request for a Sample Report: to get a more detailed analysis of the other segments https://market.us/report/flow-cytometry-market/request-sample Segment by Type Segment by key players BD, Beckman Coulter, Partec Gmbh, Thermo Fisher, Luminex Corp, Miltenyi Biotec, Intellicyt Corp, Sony(Icyt), Apogee Flow Systems, Merck KGaA (Emd millipore) Get The Complete Report To See the Analyzed Strategies of the Top Vendors to Retain or Gain Market Share https://market.us/purchase-report/?report_id=28460 The Flow Cytometry Market is a versatile technology that helps users analyze cells’ physical and chemical characteristics. This market is used in several industries, such as biotechnology, pharmaceuticals, and research laboratories. It is also used to diagnose diseases, study the effects of drugs, and understand the role of genes in cell development. The Flow Cytometry Market offers several features that benefit users, including: -The ability to measure multiple parameters simultaneously -The ability to analyze large numbers of cells quickly -The ability to sort cells based on their characteristics -The ability to detect rare events These features allow users to obtain more information about cells than other methods, making Flow Cytometry an essential tool for scientific research. Global Market Challenges Flow Cytometry 1. Even if research costs are minimal, producing Flow Cytometry is a complex and costly process. This requires significant expenditures, clinical trial experience, and process improvement. 2. Unlike generic drug creation, Flow Cytometry producers must also invest in clinical studies, and safety controls procedures comparable to those performed by original patent-holding firms. 3. Manufacturing is not easy. It’s also difficult to control the variation of the products expected to be developed. End products manufactured in different ways from those of their reference products can create problems. 4. Regulatory authorities could request additional preclinical or clinical evidence to show that the manufacturing procedure did not affect the product’s effectiveness and safety. 5. Producers of Flow Cytometry products must compete with other Flow Cytometry producers and the original biological and generic drug manufacturers. The original biologic company can be competitive by launching new products, second-generation therapies, dose enhancements, or economic manufacturing processes as new Flow Cytometry goods are introduced to the market. 6. Doctors’ perception of Flow Cytometry is still negative, which can affect their prescription to some degree. Other factors, such as patent extensions or lower prices than generic drugs, can hinder global Flow Cytometry market expansion. Review of Report Highlights @ Changes in market dynamics @ The latest industry trends and developments @ Competitive landscape @ Potential growth opportunities in niches and regions that are promising @ A neutral view of market performance @ It is essential information that market players must know to grow and sustain their market share. This Market Study Answers These Questions: 1. What is Flow Cytometry? 2. What are the benefits of using Flow Cytometry? 3. What are the challenges of using Flow Cytometry? 4. Who is the target audience for Flow Cytometry? 5. Which messages from Flow Cytometry have the greatest impact on your audience? 6. What causes product switching to occur? 7. What technological advancements have affected supplier selection criteria? MORE RELATED REPORTS FROM OUR DATABASE:
IntelliCyt Frequently Asked Questions (FAQ)
When was IntelliCyt founded?
IntelliCyt was founded in 2006.
Where is IntelliCyt's headquarters?
IntelliCyt's headquarters is located at 9620 San Mateo Blvd NE, Albuquerque.
What is IntelliCyt's latest funding round?
IntelliCyt's latest funding round is Acquired.
How much did IntelliCyt raise?
IntelliCyt raised a total of $21.38M.
Who are the investors of IntelliCyt?
Investors of IntelliCyt include Sartorius, Oxford Finance, Verge Fund, Prolog Ventures, Arboretum Ventures and 5 more.
Who are IntelliCyt's competitors?
Competitors of IntelliCyt include Gentronix Limited, Fluxion Biosciences, Sword Diagnostics, DiscoverX, Cellix and 12 more.
Compare IntelliCyt to Competitors
Fluxion Biosciences is a developer of precision solutions for life science research and diagnostics. Fluxion's liquid biopsy solutions are changing how cancer is detected and treated. Fluxion's pioneering liquid biopsy technologies include the IsoFlux CTC Liquid Biopsy System, ERASE-Seq ultra-sensitive variant caller, and the Spotlight 59 NGS Oncology Panel for cancer mutation detection from cell-free circulating tumor DNA. Fluxion's technologies are used globally by cancer centers developing new tests for early cancer detection and patient monitoring.
Sword Diagnostics is a life sciences company created in response to the needs of the research, pharmaceutical, and clinical communities. Although researchers are discovering thousands of biomarkers associated with both healthy and diseased-related biological processes, today's life science tools are unable to effectively measure, quantify, and determine the ultimate value of these biological markers. Sword Diagnostics' technology is directly aimed at making it easier to understand these newly emerging biomarkers, as well as extending the utility of existing diagnostics assays. Sword's mission is to provide the next-generation detection technology to life scientists, enabling them to continue advances in medical research, drug discovery and the provision of health care products and services.
Gentronix provides toxicology testing services for pharmaceuticals, agrochemicals, cosmetics, personal care and consumer products. The company enables major global brands to perform hazard and safety assessments, from early-stage discovery through to regulatory submission and approval.
Cira Discovery Sciences, Inc. was founded in 2003 and funded by BioAdvance in 2004 with the mission of discovering biomarker patterns for medical diagnostic products and drug discovery services. The company targets two key application domains, proteomics and flow cytometry, both utilized in the diagnostic and pharmaceutical fields. Cira has developed and patented methods of computational analysis of large, high-dimensionality data sets characteristic of both proteomics and flow cytometry. Advances in these fields are currently hampered by limitations in extracting valuable patentable knowledge from the data. The company ceased operations in 2008 and its intellectual property is being marketed for acquisition.
Vivonetics a company created through Georgia Tech's VentureLab program. The company is developing applications for molecular beacon technology in life science research and drug discovery. Its initial focus is on probes to detect RNA in living cells.
The scientists at Genomic Solutions have a wealth of genomic, protein analysis and nano-liter dispensing application-based expertise that they would like to share with users. First select their area of research, followed by interest and then application, and finally, to the company's instrumentation which can help facilitate their research. Whether users are involved in the life science or biotechnology research community, the company's products will enable users to perform complex, high volume experiments at a lower cost and in less time than traditional techniques. You achieve rapid and less expensive drug discovery.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.